Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.35 |
| ▸ | WNT1 | P04628 | 3/20 | 0.35 |
| ▸ | LYN | P07948 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29776391 | 1.00 | GSK3B (0.35) | GSK3BDYRK1AWNT1LYNSRC | |
| SCHEMBL27196862 | 0.82 | ABL1 (0.53) | GSK3BDYRK1AWNT1ABL1 | |
| SCHEMBL29776236 | 0.82 | ABL1 (0.53) | GSK3BDYRK1AWNT1ABL1 | |
| SCHEMBL29776483 | 0.80 | FYN (0.37) | GSK3BABL1MAPK1TBK1NOTUM | |
| SCHEMBL27197046 | 0.80 | FYN (0.37) | GSK3BABL1MAPK1TBK1NOTUM | |
| SCHEMBL27196991 | 0.79 | ABL1 (0.44) | GSK3BDYRK1AWNT1ABL1 | |
| SCHEMBL27196994 | 0.79 | ABL1 (0.44) | GSK3BDYRK1AWNT1ABL1 | |
| SCHEMBL27197027 | 0.79 | ABL1 (0.44) | GSK3BDYRK1AWNT1ABL1 | |
| SCHEMBL29776282 | 0.79 | ABL1 (0.41) | GSK3BDYRK1AWNT1LYNSRC | |
| SCHEMBL27197005 | 0.79 | ABL1 (0.41) | GSK3BDYRK1AWNT1LYNSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CELGENE CORPORATION (US) | 2024-04-18 | — | — | US | claimed |
| CN-116685318-A | Heterocyclic compounds and their use for parasitic diseases | 细胞基因公司 | 2023-09-01 | — | — | CN | claimed |
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CELGENE CORPORATION (US) | 2024-04-18 | — | — | US | disclosed |
| CN-116685318-A | Heterocyclic compounds and their use for parasitic diseases | 细胞基因公司 | 2023-09-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CYP11B2, CYP11B1, CYP8B1 | GSK3B 106/4885DYRK1A 1850/4885WNT1 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.